HPV variants and HLA polymorphisms: The role of variability on the risk of cervical cancer

Future Oncology

Volumn 5, Issue 3, 2009, Pages 359-370

  de Araujo Souza, Patrícia Savio ^a   Sichero, Laura ^b   Maciag, Paulo Cesar ^c  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b HOSPITAL ALEMÃO OSWALDO CRUZ   (Brazil)

^c ADVAXIS INC   (United States)

Author keywords

Cervical cancer; HLA polymorphisms; HPV; MHC; Molecular variants

Indexed keywords

HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2;

CANCER RISK; CARCINOGENESIS; DISEASE ASSOCIATION; DISEASE COURSE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HIGH RISK PATIENT; HLA SYSTEM; HOST; HUMAN; IMMUNOREGULATION; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CANCER; VIRUS CARCINOGENESIS; VIRUS CELL INTERACTION; VIRUS INFECTION; WART VIRUS;

FEMALE; GENES, MHC CLASS I; GENES, MHC CLASS II; GENES, VIRAL; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMORPHISM, GENETIC; RISK FACTORS; UTERINE CERVICAL NEOPLASMS; VIRAL PROTEINS;

EID: 66949176262     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.8     Document Type: Review

References (92)

1. Lowy DR, Solomon D, Hildesheim A, Schiller JT, Schiffman M: Human papillomavirus infection and the primary and secondary prevention of cervical cancer. Cancer 113, 1980-1993 (2008).
2. Trottier H, Franco EL: The epidemiology of genital human papillomavirus infection. Vaccine 24(Suppl. 1), S1-S15 (2006).
3. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L: Chapter 1: HPV in the etiology of human cancer. Vaccine 24(Suppl. 3), 1-10 (2006).
4. Narisawa-Saito M, Kiyono T: Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins. Cancer Sci. 98, 1505-1511 (2007).
5. Longworth MS, Laimins LA: Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol. Biol. Rev. 68, 362-372 (2004).
6. Ashrafi GH, Haghshenas MR, Marchetti B, O'Brien PM, Campo MS: E5 protein of human papillomavirus type 16 selectively downregulates surface HLA class I. Int. J. Cancer 113, 276-283 (2005).
7. Bosch FX, Burchell AN, Schiffman M et al.: Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 26 (Suppl. 10), K1-K16 (2008).
8. Trottier H, Mahmud S, Prado JC et al.: Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. J. Infect. Dis. 197, 1436-1447 (2008).
9. Dunne EF, Unger ER, Sternberg M et al.: Prevalence of HPV infection among females in the United States. JAMA 297, 813-819 (2007).
10. Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS: Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am. J. Epidemiol. 168, 123-137 (2008).
11. Walboomers JM, Jacobs MV, Manos MM et al.: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189, 12-19 (1999).
12. Wang SS, Hildesheim A: Chapter 5: viral and host factors in human papillomavirus persistence and progression. J. Natl. Cancer Inst. Monographs 31, 35-40 (2003).
13. Bernard HU, Calleja-Macias IE, Dunn ST: Genome variation of human papillomavirus types: phylogenetic and medical implications. Int. J. Cancer 118, 1071-1076 (2006).
14. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H: Classification of papillomaviruses. Virology 324, 17-27 (2004).
15. Chen Z, Terai M, Fu L, Herrero R, DeSalle R, Burk RD: Diversifying selection in human papillomavirus type 16 lineages based on complete genome analyses. J. Virol. 79, 7014-7023 (2005).
16. Arias-Pulido H, Peyton CL, Torrez-Martinez N, Anderson DN, Wheeler CM: Human papillomavirus type 18 variant lineages in United States populations characterized by sequence analysis of LCR-E6, E2, and L1 regions. Virology 338, 22-34 (2005).
17. Calleja-Macias IE, Kalantari M, Huh J et al.: Genomic diversity of human papillomavirus-16, 18, 31, and 35 isolates in a Mexican population and relationship to European, African, and Native American variants. Virology 319, 315-323 (2004).
18. Calleja-Macias IF, Villa LL, Prado JC et al.: Worldwide genomic diversity of the high-risk human papillomavirus types 31, 35, 52, and 58, four close relatives of human papillomavirus type 16. J. Virol. 79, 13630-13640 (2005).
19. Khouadri S, Villa LL, Gagnon S et al.: Human papillomavirus type 33 polymorphisms and high-grade squamous intraepithelial lesions of the uterine cervix. J. Infect. Dis. 194, 886-894 (2006).
20. Kocjan BJ, Seme K, Mocilnik T, Jancar N, Vrtacnik-Bokal E, Poljak M: Genomic diversity of human papillomavirus genotype 53 in an ethnogeographically closed cohort of white European women. J. Med. Virol. 79, 431-438 (2007).
21. Prado JC, Calleja-Macias IE, Bernard HU et al.: Worldwide genomic diversity of the human papillomaviruses-53, 56, and, 66, a group of high-risk HPVs unrelated to HPV-16 and HPV-18. Virology 340, 95-104 (2005).
22. Aho J, Hankins C, Tremblay C et al.: Genomic polymorphism of human papillomavirus type 52 predisposes toward persistent infection in sexually active women. J. Infect. Dis. 190, 46-52 (2004).
23. Gagnon S, Hankins C, Tremblay C. Forest P, Pourreaux K, Coutlee F: Viral polymorphism in human papillomavirus types 33 and 35 and persistent and transient infection in the genital tract of women. J. Infect. Dis. 190, 1575-1585 (2004).
24. Sichero L, Ferreira S, Trottier H et al.: High grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 18. Int. J. Cancer 120, 1763-1768 (2007).
25. Xi LF, Koutsky LA, Hildesheim A et al.: Risk for high-grade cervical intraepithelial neoplasia associated with variants of human papillomavirus types 16 and 18. Cancer Epidemiol. Biomarkers Prev. 16, 4-10 (2007).
26. Berumen J, Ordonez RM, Lazcano E et al.: Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control study. J. Natl Cancer Inst. 93, 1325-1330 (2001).
27. Hildesheim A, Schiffman M, Bromley C et al.: Human papillomavirus type 16 variants and risk of cervical cancer. J. Natl Cancer Inst. 93, 315-318 (2001).
28. Lizano M, De la Cruz-Hernandez E, Carrillo-Garcia A et al.: Distribution of HPV16 and 18 intratypic variants in normal cytology, intraepithelial lesions, and cervical cancer in a Mexican population. Gynecol. Oncol. 102, 230-235 (2006).
29. Burk RD, Terai M, Gravitt PE et al.: Distribution of human papillomavirus types 16 and 18 variants in squamous cell carcinomas and adenocarcinomas of the cervix. Cancer Res. 63, 7215-7220 (2003).
30. Xi LF, Kiviat NB, Hildesheim A et al.: Human papillomavirus type 16 and 18 variants: race-related distribution and persistence. J. Natl Cancer Inst. 98, 1045-1052 (2006).
31. Junes-Gill K, Sichero L, Maciag PC, Mello W, Noronha V, Villa LL: Human papillomavirus type 16 variants in cervical cancer from an admixtured population in Brazil. J. Med. Virol. 80, 1639-1645 (2008).
32. Sichero L, Trottier H, Ferreira S, Duarte-Franco E, Franco EL, Villa LL: Re: Human papillomavirus type 16 and 18 variants: race-related distribution and persistence: Comment on 98(15), 654-655. (2006), J. Natl Cancer Inst. 99(8), 653-654 (2007).
33. Lee K, Magalhaes I, Clavel C et al.: Human papillomavirus 16 E6, L1, L2 and E2 gene variants in cervical lesion progression. Virus Res. 131, 106-110 (2008).
34. Grodzki M, Besson G, Clavel C et al.: Increased risk for cervical disease progression of French women infected with the human papillomavirus type 16 E6-350G variant. Cancer Epidemiol. Biomarkers Prev. 15, 820-822 (2006).
35. Sathish N, Abraham P, Peedicayil A, Sridharan G, Chandy G: HPV 16 E6 sequence variations in Indian patients with cervical neoplasia. Cancer Lett. 229, 93-99 (2005).
36. del Refugio Gonzalez-Losa M, Laviada Mier y Teran MA, Puerto-Solis M, Garcia-Carranca A: Molecular variants of HPV type 16 E6 among Mexican women with LSIL and invasive cancer. J Clin. Virol. 29, 95-98 (2004).
37. Kang S, Jeon YT, Kim JW et al.: Polymorphism in the E6 gene of human papillomavirus type 16 in the cervical tissues of Korean women. Int. J. Gynecol. Cancer 15, 107-112 (2005).
38. Pande S, Jain N, Prust BK et al.: Human papillomavirus type 16 variant analysis of E6, E7, and L1 genes and long control region in biopsy samples from cervical cancer patients in north India. J. Clin. Microbiol. 46, 1060-1066 (2008).
39. Rajeevan MS, Swan DC, Nisenbaum R et al.: Epidemiologic and viral factors associated with cervical neoplasia in HPV-16-positive women. Int. J. Cancer 115, 114-120 (2005).
40. Vaeteewoottacharn K, Jearanaikoon P, Ponglikitmongkol M: Co-mutation of HPV16 E6 and E7 genes in Thai squamous cervical carcinomas. Anticancer Res. 23, 1927-1931 (2003).
41. Chakrabarti O, Veeraraghavalu K, Tergaonkar V et al.: Human papillomavirus type 16 E6 amino acid 83 variants enhance E6-mediated MAPK signaling and differentially regulate tumorigenesis by notch signaling and oncogenic Ras. J. Virol. 78, 5934-5945 (2004).
42. Asadurian Y, Kurilin H, Lichtig H et al.: Activities of human papillomavirus 16 E6 natural variants in human keratinocytes. J. Med. Virol. 79, 1751-1760 (2007).
43. Lichtig H, Algrisi M, Boczer LE et al.: HPV16 E6 natural variants exhibit different activities in functional assays relevant to the carcinogenic potential of E6. Virology 350, 216-227 (2006).
44. Hu J, Cladel NM, Pickel MD, Christensen ND. Amino acid residues in the carboxy-terminal region of cottontail rabbit papillomavirus E6 influence spontaneous regression of cutaneous papillomas. J. Virol. 76, 11801-11808 (2002).
45. Matsumoto K, Yoshikawa H, Nakagawa S et al: Enhanced oncogenicity of human papillomavirus type 16 (HPV16) variants in Japanese population. Cancer Lett. 156, 159-165 (2000).
46. Chan PK, Lam CW, Cheung TH et al.: Association of human papillomavirus type 58 variant with the risk of cervical cancer. J. Natl Cancer Inst. 94, 1249-1253 (2002).
47. Gagnon S, Hankins C, Money D, Pourreaux K, Franco E, Coutlee F: Polymorphisin of the L1 capsid gene and persistence of human papillomavirus type 52 infection in women at high risk or infected by HIV. J. Acquir. Immune Defic. Syndr. 44, 61-65 (2007).
48. Sichero L, Franco EL, Villa LL: Different P105 promoter activities among natural variants of human papillomavirus type 18. J. Infect. Dis. 191, 739-742 (2005).
49. Ndisang D, Faulkes DJ, Gascoyne D et al.: Differential regulation of different human papilloma virus variants by the POU family transcription factor Brn-3a. Oncogene 25, 51-60 (2006).
50. Hubert WG: Variant upstream regulatory region sequences differentially regulate human papillomavirus type 16 DNA replication throughout the viral life cycle. J. Virol. 79, 5914-5922 (2005).
51. De la Cruz-Hernandez E, Garcia-Carranca A, Mohar-Betancourt A et al.: Differential splicing of E6 within human papillomavirus type 18 variants and functional consequences. J. Gen. Virol. 86, 2459-2468 (2005).
52. Choo KB, Wang TS, Huang CJ: Analysis of relative binding affinity of E7-pRB of human papillomavirus 16 clinical variants using the yeast two-hybrid system. J. Med. Virol. 61, 298-302 (2000).
53. Ordonez RM, Espinosa AM, Sanchez- Gonzalez DJ, Armendariz-Borunda J, Berumen J: Enhanced oncogenicity of Asian-American human papillomavirus 16 is associated with impaired E2 repression of E6/E7 oncogene transcription. J. Gen. Virol. 85, 1433-1444 (2004).
54. Nath R, Mant CA, Kell B, Cason J, Bible JM: Analyses of variant human papillomavirus type 16 E5 proteins for their ability to induce mitogenesis of murine fibroblasts. Cancer Cell Int. 6, 19 (2006).
55. Yang R, Wheeler CM, Chen X et al.: Papillomavirus capsid mutation to escape dendritic cell-dependent in innate immunity in cervical cancer. J. Virol. 79, 6741-6750 (2005).
56. Stanley M: Immune responses to human papillomavirus. Vaccine 24 (Suppl. 1), S16-S22 (2006).
57. Horton R, Wilming L, Rand V et al.: Gene map of the extended human MHC. Nat. Rev. Genet. 5, 889-899 (2004).
58. Zoodsma M, Nolte IM, Schipper M et al.: Analysis of the entire HLA region in susceptibility for cervical cancer: a comprehensive study. J. Med. Genet. 42, E49 (2005).
59. Engelmark M, Beskow A, Magnusson J, Erlich H, Gyllensten U: Affected sib-pair analysis of the contribution of HLA class I and class II loci to development of cervical cancer Hum. Mol. Genet. 13, 1951-1958 (2004).
60. Arias-Pulido H, Joste N, Wheeler CM: Loss of heterozygosity on chromosome 6 in HPV-16 positive cervical carcinomas carrying the DRB1*1501-DQB1*0602 haplotype. Genes Chromosomes Cancer 40, 277-284 (2004).
61. de Araujo Souza PS, Villa LL: Genetic susceptibility to infection with human papillomavirus and development of cervical cancer in women in Brazil. Mutat. Res. 544, 375-383 (2003).
62. Beskow AH, Josefsson AM, Gyllensten UB: HLA class II alleles associated with infection by HPV16 in cervical cancer in situ. Int. J. Cancer 93, 817-822 (2001).
63. Beskow AH, Gyllensten UB: Host genetic control of HPV 16 titer in carcinoma in situ of the cervix uteri. Int. J. Cancer 101, 526-531 (2002).
64. Ades S, Koushik A, Duarte-Franco E et al.: Selected class I and class II HLA alleles and haplotypes and risk of high-grade cervical intraepithelial neoplasia. Int. J. Cancer 122, 2820-2826 (2008)
65. Hildesheim A, Schiffman M. Scott DR et al.: Human leukocyte antigen class I/II alleles and development of human papillomavirus- related cervical neoplasia: results from a case-control study conducted in the United States. Cancer Epidemiol. Biomarkers Prev. 7, 1035-1041 (1998).
66. Maciag PC, Schlecht NF, Sonza PS, Rohan TE, Franco EL, Villa LL: Polymorphisms of the human leukocyte antigen DRB1 and DQB1 genes and the natural history of human papillomavirus infection. J. Infect. Dis. 186, 164-172 (2002).
67. Mahmud SM, Robinson K, Richardson H et al.: HLA polymorphisms and cervical human papillomavirus infection in a cohort of Montreal University students. J. Infect. Dis. 196, 82-90 (2007).
68. Zhu J, Paul WE: CD4 T cells: fares, functions, and faults. Blood 112, 1557-1569 (2008).
69. Murphy KM, Reiner SL: The lineage decisions of helper T cells. Nat. Rev. Immunol. 2, 933-944 (2002).
70. + T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes. Clin. Cancer Res. 10, 3301-3308 (2004).
71. + regulatory T cell: a jack of all trades, master of regulation. Nat. Immunol. 9, 239-244 (2008).
72. + regulatory T cells specific for human papillomavirus antigens. Proc. Natl Acad. Sci. USA 104, 12087-12092 (2007).
73. + T cells. J. Exp. Med. 197, 1017-1028 (2003).
74. Lukic A, Canzio C, Patella A et al.: Determination of cervicovaginal microorganisms in women with abnormal cervical cytology: the role of ureaplasma urealyticum. Anticancer Res. 26, 4843-4849 (2006).
75. Castle PE, Giuliano AR: Chapter 4: genital tract infections, cervical inflammation, and antioxidant nutrients - assessing their roles as human papillomavirus cofactors. J. Natl. Cancer Inst. Monographs 31, 29-34 (2003).
76. + T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer. Cancer Res. 65, 2018-2025 (2005).
77. Vambutas A, Bonagura VR, Steinberg BM: Altered expression of TAP-1 and major histocompatibility complex class I in laryngeal papillomatosis: correlation of TAP-1 with disease. Clin. Diagn. Lab. Immunol. 7, 79-85 (2000).
78. Madeleine MM, Johnson LG, Smith AG et al.: Comprehensive analysis of HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 loci and squamous cell cervical cancer risk. Cancer Res. 68, 3532-3539 (2008).
79. Carrington M, Wang S, Martin MP et al.: Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J. Exp. Med. 201, 1069-1075 (2005).
80. Matsumoto K, Yasugi T, Nakagawa S et al.: Human papillomavirus type 16 E6 variants and HLA class II alleles among Japanese women with cervical cancer. Int. J. Cancer 106, 919-922 (2003).
81. de Araujo Souza PS, Maciag PC, Ribeiro KB, Petzl-Erler ML, Franco EL, Villa LL: Interaction between polymorphisms of the human leukocyte antigen and HPV-16 variants on the risk of invasive cervical cancer. BMC Cancer 8, 246 (2008).
82. Cuzick J, Terry G, Ho L et al.: Association between high-risk HPV types, HLA DPB1* and DQB1* alleles and cervical cancer in British women. Br. J. Cancer 82, 1348-1352 (2000).
83. Beskow AH, Engelmark MT, Magnusson JJ, Gyllensten UB: Interaction of host and viral risk factors for development of cervical carcinoma in situ. Int. J. Cancer 117, 690-692 (2005).
84. Zehbc 1, Tachezy R, Mytilineos J et al.: Human papillomavirus 16 E6 polymorphisms in cervical lesions from different European populations and their correlation with human leukocyte antigen class II haplotypes. Int. J. Cancer 94, 711-716 (2001).
85. Zehbe I, Mytilineos J, Wikstrom I, Henriksen R, Filler L, Tommashio M: Association between human papillomavirus 16 E6 variants and human leukocyte antigen class I polymorphism in cervical cancer of Swedish women. Hum. Immunol. 64, 538-542 (2003).
86. Schreurs MW, Kueter EW, Scholten KB, Lemonnier FA, Meijer CJ, Hooijberg E: A single amino acid substitution improves the in vivo immunogenicity of the HPV16 oncoprotein E7(11-20) cytotoxic T lymphocyte epitope. Vaccine 23, 4005-4010 (2005).
87. Liu XS, Xu Y, Hardy L et al.: IL-10 mediates suppression of the CD8 T cell IFN-γ response to a novel viral epitope in a primed host. J. Immunol. 171, 4765-4772 (2003).
88. Liu XS, Dyer J, Leggatt GR et al.: Overcoming original antigenic sin to generate new CD8 T cell IFN-γ responses in an antigen-experienced host. J. Immunol. 177, 2873-2879(2006).
89. Terry G, Ho L, Cuzick J: Analysis of E2 amino acid variants of human papillomavirus types 16 and 18 and their associations with lesion grade and HLA DR/DQ type. Int. J. Cancer 73, 651-655 (1997).
90. Bontkes HJ, van Duin M, de Gruijl TD et al.: HPV 16 infection and progression of cervical intra-epithelial neoplasia: analysis of HLA polymorphism and HPV 16 E6 sequence variants. Int. J. Cancer 78, 166-171 (1998).
91. Brady CS, Duggan-Keen MF, Davidson JA, Varley JM, Stern PL: Human papillomavirus type 16 E6 variants in cervical carcinoma: relationship to host genetic factors and clinical parameters. J. Gen. Virol. 80 (Part 12), 3233-3240 (1999).
92. Chan PK, Cheung JL, Cheung TH et al.: HLA-DQB1 polymorphisms and risk for cervical cancer: a case-control study in a southern Chinese population. Gynecol. Oncol. 105, 736-741 (2007).